Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause C-reactive protein increased? 2,309 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 2,309 reports of C-reactive protein increased have been filed in association with TOFACITINIB (XELJANZ XR). This represents 1.5% of all adverse event reports for TOFACITINIB.

2,309
Reports of C-reactive protein increased with TOFACITINIB
1.5%
of all TOFACITINIB reports
929
Deaths
1,203
Hospitalizations

How Dangerous Is C-reactive protein increased From TOFACITINIB?

Of the 2,309 reports, 929 (40.2%) resulted in death, 1,203 (52.1%) required hospitalization, and 858 (37.2%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 2,309 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which TOFACITINIB Alternatives Have Lower C-reactive protein increased Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased TOFACITINIB Demographics